

Liang Peng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7986463/publications.pdf>

Version: 2024-02-01

13
papers

162
citations

1040056

9
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

250
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolving landscape and academic attitudes toward the controversies of global immuno-oncology trials. <i>International Journal of Cancer</i> , 2021, 149, 108-118.	5.1	5
2	Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2021, 10, 8272-8287.	2.8	5
3	A New Model for Predicting Hypothyroidism After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 551255.	2.8	13
4	Treatment effects of cumulative cisplatin dose during radiotherapy following induction chemotherapy in nasopharyngeal carcinoma: propensity score analyses. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093742.	3.2	5
5	Thyroid dose-volume thresholds for the risk of radiation-related hypothyroidism in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A single-institution study. <i>Cancer Medicine</i> , 2019, 8, 6887-6893.	2.8	19
6	The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma. <i>Radiation Oncology</i> , 2019, 14, 9.	2.7	22
7	The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma. <i>British Journal of Radiology</i> , 2019, 92, 20181031.	2.2	20
8	Necessity of concurrent chemotherapy in N2a-c nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of 3 cycles followed by intensity-modulated radiotherapy. <i>Cancer Medicine</i> , 2019, 8, 2823-2831.	2.8	12
9	Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma: Dose-effect analysis for a large cohort. <i>Oral Oncology</i> , 2019, 89, 102-106.	1.5	16
10	The Efficacy and Safety of Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Nasopharyngeal Carcinoma: Literature-based Meta-analyses. <i>Journal of Cancer</i> , 2018, 9, 4510-4520.	2.5	9
11	A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVA nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2018, 86, 258-265.	1.5	6
12	Relationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation. <i>Cancer Medicine</i> , 2018, 7, 5988-5998.	2.8	18
13	Optimal Modality for Detecting Distant Metastasis in Primary Nasopharyngeal Carcinoma during Initial Staging: A Systemic Review and Meta-analysis of 1774 Patients. <i>Journal of Cancer</i> , 2017, 8, 1238-1248.	2.5	12